Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterNo recent work listed

Steven J. Cohen

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5103737583. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 2, last author 5)
Trials
5 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
102
Papers, trials and grants by year

2003: 1 trial · 2004: 1 trial · 2005: none · 2006: none · 2007: 1 trial · 2008: 2 trials · 2009: none · 2010: none · 2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 4 papers · 2015: 5 papers · 2016: 4 papers · 2017: none · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers

Papers 26

  1. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Co-author DOI 10.1016/j.ejca.2023.02.030↗
  2. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. Co-author DOI 10.1200/po.22.00648↗
  3. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-021-10219-3↗
  4. Trends in Palliative Care, Hospice Utilization, and Outcomes in Hospitalized Pancreatic Cancer Patients: A Nationwide Analysis. First author DOI 10.7759/cureus.29351↗
  5. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. Co-author DOI 10.1016/j.ejca.2021.01.004↗
  6. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Last author DOI 10.1007/s10637-019-00824-1↗
  7. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. Co-author DOI 10.1016/j.jgo.2019.12.013↗
  8. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  9. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000227↗
  10. A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve… Co-author DOI 10.1097/coc.0000000000000260↗
  11. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic … Co-author DOI 10.1007/s00280-016-2981-2↗
  12. Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer. Co-author DOI 10.1016/j.prro.2015.11.005↗
  13. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000619↗
  14. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? First author DOI 10.21037/jgo.2016.08.01↗
  15. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  16. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience. Last author DOI 10.1016/j.jgo.2015.08.001↗
  17. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Co-author DOI 10.1016/j.prro.2015.04.004↗
  18. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv264↗
  19. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
  20. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advan… Last author DOI 10.1016/j.radonc.2014.08.014↗
  21. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. Co-author DOI 10.1111/hpb.12058↗
  22. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery ma… Co-author DOI 10.1245/s10434-013-3396-5↗
  23. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  24. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗
  25. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcin… Last author DOI 10.1097/coc.0b013e3181d2734a↗
  26. Significance of pathologic response to preoperative therapy in pancreatic cancer. Co-author DOI 10.1245/s10434-011-2086-4↗

Trials 5

  1. A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer Principal investigator NCT00637247↗
  2. Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer Principal investigator NCT00761345↗
  3. Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery Principal investigator NCT00900016↗
  4. Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma Principal investigator NCT00327327↗
  5. Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Study chair NCT00066677↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Efrat Dotan · 6 shared papers, 2015–2022 · strength 0.58
  2. John Parker Hoffman · 9 shared papers, 2011–2022 · strength 0.53
  3. Bert H. O’Neil · 7 shared papers, 2015–2023 · strength 0.53
  4. Joshua E. Meyer · 7 shared papers, 2014–2022 · strength 0.49
  5. Talha Shaikh · 4 shared papers, 2015–2022 · strength 0.36
  6. Atrayee Basu Mallick · 2 shared papers, 2021–2023 · strength 0.30
  7. Charles J. Yeo · 2 shared papers, 2021–2023 · strength 0.30
  8. Namrata Vijayvergia · 3 shared papers, 2015–2020 · strength 0.30
  9. Wells A. Messersmith · 4 shared papers, 2015–2020 · strength 0.27
  10. Jordan D. Berlin · 4 shared papers, 2015–2020 · strength 0.23
  11. Lora S. Wang · 3 shared papers, 2015–2018 · strength 0.22
  12. Shreeja Shah · 1 shared paper, 2022 · strength 0.20
  13. Kuldeepsinh Pradipkumar Atodaria · 1 shared paper, 2022 · strength 0.20
  14. Safi Shahda · 2 shared papers, 2020 · strength 0.20
  15. Heinz‐Josef Lenz · 2 shared papers, 2020 · strength 0.20
  16. Dana Backlund Cardin · 2 shared papers, 2020 · strength 0.20
  17. Igor A. Astsaturov · 4 shared papers, 2011–2020 · strength 0.20
  18. Colin D. Weekes · 3 shared papers, 2014–2020 · strength 0.18
  19. Patrick Joseph Loehrer · 1 shared paper, 2023 · strength 0.17
  20. Walid Labib Shaib · 1 shared paper, 2023 · strength 0.17
  21. Tanios Bekaii‐Saab · 1 shared paper, 2023 · strength 0.17
  22. Bassel F. El‐Rayes · 1 shared paper, 2023 · strength 0.17
  23. Emanuel F. Petricoin · 1 shared paper, 2023 · strength 0.15
  24. Ida Micaily · 1 shared paper, 2023 · strength 0.15
  25. Harish Lavu · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.